ELMMB logo
Facebook logo Twitter logo
Menu
Drug Alerts and Withdrawals

Drug Alerts and Withdrawals

Within the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health aim to enhance and safeguard the health of the public by ensuring that medicines and medical devices work and are acceptably safe. No product is risk-free. Underpinning their work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.

  • The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe.
  • No product is risk-free. Underpinning the work of the MHRA lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.
  • The MHRA keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem.
  • The MHRA aim to make as much information as possible publicly available. The MHRA enable greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public.
  • The MHRA encourage everyone - the public and healthcare professionals as well as industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. To find out more about the MHRA click here...

When the MHRA, or occasionally another regulatory body in another country, such as the FDA, release advice, it is sometime necessary to produce additional local guidance.  This aims to be both clear and concise advice to healthcare professionals on the local action required to implement or respond to alerts issued by the MHRA or other bodies.  These memorandums are available below for reference, once they have been circulated to the relevant professionals in primary and secondary care:

MHRA News Stories.

 26th May 2020              MHRA Press Release - MHRA supports use of remdesivir as the first medicines to treat COVID-19 in the UK
 6th May 2020                MHRA Press Release - NEW Yellow Card COVID-19 reporting site
12th February 2020      MHRA Press Release  - Integrated Yellow Card reporting now available in 93% of GP practices in the UK
19th November 2019   MHRA Press Release - Ranitidine Oral Solution & Tablets recall
                                                     
                                                 


MHRA Company-led Drug alerts

click here to access the most recent alerts

Items In This Category

 TitleCreatedDownload
application/pdfSodium Benzoate 2g in 10mL sol for inj Class 4 meds recall 280520 Final.pdf (48KB)28/05/2020Download
  
application/pdfEmerade 500mcg pfs class 2 medicines rceall 180520EL__20_A_23_Final.pdf (333KB)18/05/2020Download
  
application/pdfLevofloxacin 500mg tab class 4 meds recall 160420_Final.pdf (242KB)16/04/2020Download
 TEVA UK Limited has informed us that the Product Code/GTIN (PC) number found on the above batches is incorrect. The GTIN number that should have been allocated for this batch of tablets is... 
application/pdfEmerade 300mcg pen Class 2 meds recall EL__20_A_20_Final.pdf (340KB)09/04/2020Download
  
application/pdfEsmya 5mg Class 2 meds recallEL__20_A_16_Final.pdf (120KB)09/04/2020Download
  
application/pdfEmerade 150 mcg sol for inj Class 2 meds recal 0320_Final.pdf (348KB)05/03/2020Download
 Pharmaswiss ńĆeska republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerade 150 microgram auto-injectors (also referred to as pens) from patients due... 
application/pdfIbuprofen 400mg Class 4 Medicines recallEL__20_A_10_FInal__002_.pdf (173KB)21/02/2020Download
 Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed us that the Patient Information Leaflet (PIL) within their packs for the above pharmacy (P) batches is incorrect. The PIL in the above... 
application/pdfDiamorphine Hcl BP 100mg lyophilisate for soln for inj Cl 4 meds defect info 0220_Final.pdf (138KB)17/02/2020Download
 Accord Healthcare Ltd has informed us of an issue related to the expiry date for the batches in this alert, which has not been encoded in 2D data matrix. Upon FMD scanning verification and... 
application/pdfAtrolak XL 50mg PL tabs Cl4 meds recakk EL__20_A_06_Final 0220.pdf (90KB)12/02/2020Download
 Accord Healthcare Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the above batches is missing the side effects identified from post-marketing experience that are... 
application/pdfFinasteride_meds defect information EL__20_A_030120.pdf (107KB)29/01/2020Download
 Dr. Reddy's Laboratories (UK) Ltd has informed us that the Patient Information Leaflet (PIL) for the above batches is missing the special warning and precautions identified from post-marketing... 
application/pdfPicato 150mcg per g gel Class 2 medicines recall 270120.pdf (196KB)27/01/2020Download
 LEO Laboratories Ltd (T/A LEO Pharma) is recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to concerns on the possible risk of skin... 
application/pdfRanitidine 150mg 300mg tablets Medley Pharma EL__19_A_41_Final.pdf (100KB)17/12/2019Download
 Medley Pharma Limited is recalling all unexpired stock of the above products from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity... 
Page: [1] [2] [3] [4] [5] [6]
[ Next » ]